<DOC>
	<DOCNO>NCT00326469</DOCNO>
	<brief_summary>To evaluate , patient progressive neuroendocrine tumour eligible treat either surgery chemotherapy moment study inclusion , efficacy lanreotide Autogel tumour growth stabilization .</brief_summary>
	<brief_title>Efficacy Safety Lanreotide Autogel Tumour Stabilization Patients With Progressive Neuroendocrine Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>patient histopathologic diagnosis welldifferentiated neuroendocrine tumour carcinoma accord WHO classification patient , accord RECIST criterion ( Response Evaluation Criteria Solid Tumours ) present measurable disease patient progressive disease previous 6 month inclusion study patient positive IN111 octreotide scintigraphy patient surgically removable localised disease patient progressive disease first six month diagnose patient intestinal obstruction due carcinoid tumour patient receive treatment somatostatin analogues 6 month include study patient receive treatment radiotherapy , chemotherapy interferon 4 week include study , plan receive study patient receive treatment liver artery embolisation radiopharmaceutical ( endoradiotherapy ) 12 week include study , plan study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>